incid
rvi
follow
hsct
rang
older
studi
like
underestim
incid
howev
rvi
detect
methodolog
use
gener
less
sensit
limit
fewer
virus
outcom
rvi
hsct
recipi
depend
sever
factor
includ
whether
transplant
myeloabl
versu
nonmyeloabl
presenc
lymphopenia
intens
immunosuppress
one
seri
larg
cancer
center
rvi
patient
hematolog
malign
hsct
identifi
period
progress
lower
respiratori
infect
occur
patient
depend
type
infect
viru
risk
factor
progress
includ
underli
diagnosi
leukemia
age
greater
year
sever
neutropenia
lymphopenia
lymphopenia
risk
factor
allogen
autolog
hsct
also
identifi
studi
lower
tract
infect
common
receiv
myeloabl
condit
nonmyeloabl
transplant
asid
direct
morbid
mortal
rvi
may
also
risk
factor
develop
invas
aspergillosi
allogen
hsct
whether
repres
overal
immunosuppress
state
need
studi
incid
rvi
sot
recipi
lung
transplant
recipi
seem
greater
frequenc
rvi
sot
recipi
like
direct
commun
allograft
environ
poor
immun
respons
allograft
risk
progress
lower
tract
diseas
well
defin
howev
like
depend
time
posttranspl
intens
immunosuppress
type
transplant
poor
immun
respons
allograft
lung
transplant
recipi
like
greater
risk
lower
tract
diseas
signific
overlap
symptom
respiratori
virus
difficult
distinguish
clinic
respiratori
viru
caus
symptom
given
patient
common
symptom
upper
respiratori
tract
ill
includ
malais
sore
throat
coryza
cough
fever
presenc
dyspnea
may
signal
lower
respiratori
tract
infect
lrti
viru
bacteri
superinfect
chest
radiograph
may
show
diffus
interstiti
infiltr
also
show
airspac
diseas
common
chest
ct
find
groundglass
attenu
centrilobular
nodul
mm
size
includ
treeinbud
appear
also
seen
airspac
consolid
present
one
third
patient
ct
chest
scan
crazypav
pattern
describ
highresolut
chest
ct
scan
consist
interlobular
intralobular
septal
thicken
superimpos
area
groundglass
opacif
although
specif
rvi
one
studi
found
patient
pattern
viral
pneumon
progress
upper
tract
lower
tract
infect
occur
although
incid
quit
variabl
like
caus
vari
immunosuppress
time
infect
transplant
underli
diseas
asymptomat
shed
respiratori
virus
shown
occur
solid
organ
hsct
recipi
transplant
recipi
postul
superspread
viru
given
high
viral
load
respiratori
virus
found
respiratori
secret
addit
prolong
shed
respiratori
virus
often
note
transplant
recipi
may
serv
sentin
given
infect
commun
may
first
becom
infect
emerg
viru
signal
begin
outbreak
tradit
laboratori
diagnosi
respiratori
virus
difficult
limit
rel
virus
past
acut
convalesc
sera
use
diagnos
viral
infect
transplant
oncolog
patient
howev
humor
respons
viral
infect
often
detect
significantli
delay
viru
isol
cell
line
also
use
tube
cultur
result
gener
avail
day
lead
delay
diagnosi
direct
fluoresc
antibodi
dfa
test
use
nasopharyng
aspir
swab
avail
clinic
laboratori
provid
rapid
result
hour
test
commonli
limit
howev
influenza
b
parainfluenza
rsv
adv
also
limit
sensit
detect
recognit
virus
cov
includ
sever
acut
respiratori
syndrom
sar
associ
cov
hmpv
rhinoviru
signific
pathogen
lead
diseas
nucleic
acid
amplif
test
nat
taken
lead
role
diagnosi
rvi
multiplex
polymeras
chain
reaction
pcr
microbead
detect
dna
microarray
capabl
search
sever
virus
one
test
molecular
detect
sever
respiratori
virus
simultan
use
natbas
assay
use
sever
clinic
laboratori
detect
studi
virus
human
bocaviru
depend
nat
gener
nat
test
sensit
method
one
issu
sensit
method
detect
asymptomat
viral
infect
one
studi
hsct
recipi
test
nasal
wash
specimen
patient
first
day
posttranspl
convent
dfa
pcr
pcr
significantli
increas
yield
virus
howev
virus
detect
pcr
lower
viral
load
mani
repres
asymptomat
infect
coinfect
two
respiratori
virus
may
also
detect
use
sensit
method
case
may
difficult
determin
toward
viru
treatment
direct
influenza
neg
sens
singlestrand
rna
viru
orthomyxovirida
famili
influenza
virus
undergo
antigen
chang
high
frequenc
smaller
antigen
chang
term
antigen
drift
produc
minor
variat
surfac
glycoprotein
substitut
antibodybind
site
result
reinfect
larger
antigen
shift
occur
reassort
gene
howev
two
influenza
virus
simultan
infect
one
host
antigen
shift
also
occur
result
direct
mutat
allow
crossspeci
infect
complic
influenza
infect
seem
common
hsct
sot
popul
seem
rel
high
rate
progress
viral
pneumonia
report
especi
lung
transplant
recipi
hsct
recipi
one
studi
organ
transplant
recipi
period
rate
influenza
infect
rang
case
per
person
year
liver
transplant
case
per
person
year
lung
transplant
complic
includ
secondari
bacteri
pneumonia
extrapulmonari
complic
myocard
myositi
observ
contrast
report
ljungman
colleagu
influenza
case
renal
transplant
recipi
one
patient
develop
viral
pneumonia
one
bronchiti
remain
patient
recov
without
complic
sever
diseas
commonli
report
hsct
recipi
attribut
mortal
rate
high
larg
review
hsct
recipi
influenza
show
pneumonia
develop
infect
sooner
posttranspl
lymphopenia
patient
treat
antivir
progress
pneumonia
shed
longer
respiratori
viru
transplant
steroid
dose
greater
mgkgd
suggest
oseltamivir
may
decreas
shed
recent
review
patient
influenza
none
upper
respiratori
tract
infect
urti
progress
lrti
mortal
although
patient
treat
oseltamivir
shed
present
median
day
correl
invers
presenc
lymphopenia
lymphopenia
absolut
lymphocyt
count
cellsml
specif
risk
factor
identifi
progress
influenza
pneumonia
influenza
b
infect
follow
autolog
hsct
also
associ
mortal
pediatr
cancer
patient
influenza
also
import
caus
morbid
diagnosi
influenza
made
use
sever
method
serolog
viru
cultur
dfa
pcr
nasopharyng
swab
lower
respiratori
sampl
use
therapi
influenza
b
neuraminidas
inhibitor
oseltamivir
zanamivir
mainstay
manag
tabl
immunosuppress
host
oseltamivir
start
time
cours
ill
oral
dose
mg
twice
daili
five
day
dose
mg
twice
daili
also
suggest
expert
extend
therapeut
cours
patient
remain
symptomat
day
zanamivir
sialic
acid
analog
avail
inhal
prepar
shown
effect
influenza
gener
popul
start
within
hour
symptom
onset
zanamivir
also
use
success
hsct
recipi
influenza
b
recommend
dose
zanamivir
mg
two
puff
twice
daili
day
studi
johni
colleagu
zanamivir
use
viral
excret
ceas
concern
also
rais
regard
pulmonari
bioavail
zanamivir
immunocompromis
patient
futur
clinic
trial
area
use
combin
antivir
transplant
popul
need
resist
oseltamivir
develop
larg
proport
influenza
virus
influenza
influenza
b
virus
convers
virus
high
rate
resist
zanamivir
remain
suscept
oseltamivir
inhibitor
class
amantadin
rimantadin
also
use
transplant
recipi
influenza
use
limit
side
effect
antivir
resist
ribavirin
also
vitro
activ
influenza
could
potenti
use
combin
antivir
addit
novel
compound
peramivir
combin
antivir
therapi
also
studi
clinic
trial
commonli
use
trival
inactiv
subunit
vaccin
revis
annual
contain
two
influenza
one
influenza
b
strain
vaccin
recommend
transplant
recipi
transplant
candid
household
contact
health
care
worker
contact
immunocompromis
patient
immunogen
vaccin
variabl
depend
popul
studi
hsct
recipi
vaccin
respons
absent
month
posttranspl
recommend
wait
month
administ
vaccin
similarli
sot
recipi
vaccin
administ
time
month
posttranspl
data
support
acut
chronic
reject
consequ
vaccin
popul
intranas
prepar
live
attenu
vaccin
recommend
immunocompromis
popul
pandem
influenza
particular
concern
transplant
oncolog
center
current
pandem
swine
origin
viru
like
aros
crossspeci
adapt
viru
swinetohuman
success
humantohuman
transmiss
time
write
person
report
infect
death
worldwid
risk
factor
sever
diseas
includ
infant
less
year
underli
lung
diseas
diabet
pregnanc
immunosuppress
patient
also
risk
sever
diseas
although
specif
data
transplant
oncolog
patient
howev
greater
knowledg
becom
avail
risk
factor
sever
diseas
death
clearli
defin
impact
transplant
program
part
depend
virul
viru
amount
resourc
requir
manag
critic
ill
patient
parainfluenza
virus
piv
compris
group
four
serotyp
singlestrand
rna
paramyxovirus
piv
occur
yearround
caus
number
clinic
syndrom
includ
croup
bronchiol
common
cold
pneumonia
transplant
recipi
spectrum
piv
rang
asymptomat
respiratori
failur
death
larg
retrospect
review
hsct
patient
upper
respiratori
infect
surviv
pneumonia
univers
mortal
despit
ribavirin
therapi
asymptomat
parainfluenza
infect
respiratori
viru
transplant
detect
surveil
studi
hsct
patient
could
possibl
mode
transmiss
outbreak
particular
caus
nosocomi
outbreak
hsct
unit
result
persontoperson
transmiss
mortal
rate
seen
outbreak
situat
syndrom
transplant
associ
piv
includ
guillainbarr
e
syndrom
acut
dissemin
encephalomyel
parot
lung
transplant
recipi
incid
piv
estim
patient
lrti
occur
bronchiol
obliteran
syndrom
bo
longterm
consequ
infect
radiolog
featur
includ
peribronchi
small
nodul
less
mm
diamet
ct
chest
intraven
oral
ribavirin
use
therapi
infect
transplant
recipi
conflict
result
respiratori
syncyti
viru
rsv
possibl
import
caus
morbid
mortal
respiratori
virus
affect
transplant
recipi
rsv
caus
sever
lower
respiratori
tract
diseas
transplant
patient
one
studi
risk
factor
progress
rsv
lack
rsvdirect
antivir
therapi
age
pediatr
studi
lymphopenia
age
less
year
also
shown
import
risk
factor
progress
rsvrelat
mortal
children
treat
acut
myeloid
leukemia
diagnosi
rsv
perform
use
standard
dfa
techniqu
cultur
nat
xtag
rvp
assay
report
sensit
rsv
detect
specif
rang
primari
therapi
studi
aerosol
ribavirin
given
g
three
time
day
g
hour
logist
cost
issu
aerosol
therapi
limit
use
mani
center
neg
pressur
room
must
use
drug
teratogen
close
contact
small
random
trial
aerosol
ribavirin
versu
standard
care
upper
respiratori
rsv
infect
hsct
recipi
show
decreas
viral
load
ribavirin
arm
differ
progress
pneumonia
oral
ribavirin
suggest
altern
studi
five
lung
transplant
recipi
oral
ribavirin
puls
solumedrol
mgkgd
day
given
rsv
lrti
welltoler
seem
effect
case
seri
lung
transplant
recipi
rsv
given
intraven
ribavirin
corticosteroid
mortal
seen
although
hemolyt
anemia
occur
palivizumab
monoclon
antibodi
specif
rsv
also
use
conjunct
antivir
treatment
rsv
pneumonia
survey
pediatr
sot
center
unit
state
show
center
use
rsv
prophylaxi
use
palivizumab
infant
month
anoth
human
monoclon
antibodi
motavizumab
investig
addit
rnai
molecul
silenc
nucleocapsid
gene
rsv
genom
also
clinic
trial
vaccin
avail
although
clinic
trial
ongo
hmpv
negativesens
nonseg
rna
paramyxoviru
close
relat
structur
rsv
increasingli
recogn
caus
upper
lower
respiratori
infect
winter
month
incid
hsct
patient
retrospect
hmpv
found
caus
infect
hsct
patient
diagnos
idiopath
pneumonia
unknown
often
hmpv
upper
tract
infect
progress
lower
tract
infect
howev
fatal
case
progress
respiratori
failur
earli
posttransplant
describ
persist
asymptomat
hmpv
also
recogn
hsct
recipi
lung
transplant
hmpv
infect
seem
symptomat
lead
graft
dysfunct
diagnosi
hmpv
base
nucleic
acid
detect
support
care
mainstay
treatment
reduct
immunosuppress
may
benefit
ribavirin
shown
activ
vitro
anim
model
well
report
success
treatment
human
case
ribavirin
without
concomit
immun
globulin
candid
vaccin
hmpv
investig
anim
model
cov
includ
sar
cov
cov
also
emerg
import
caus
upper
lower
tract
rvi
transplant
incid
human
cov
hcov
transplant
recipi
like
underestim
limit
diagnost
test
increas
use
nat
howev
strain
hcov
describ
transplant
recipi
includ
sar
prospect
studi
identifi
hcov
bronchoalveolar
lavag
fluid
specimen
transplant
lung
liver
common
underli
medic
condit
occur
almost
half
patient
prospect
studi
lung
transplant
recipi
coronaviru
compris
specimen
posit
respiratori
virus
lead
signific
shortand
longterm
declin
forc
expiratori
pressur
second
sever
case
also
describ
earli
posthsct
diagnosi
cov
base
nucleic
acid
detect
cultur
use
human
hepatoma
cell
line
serolog
also
use
specif
therapi
cov
infect
outbreak
sever
respiratori
ill
describ
china
hong
kong
canada
eventu
affect
person
sever
countri
worldwid
predominantli
health
careassoci
outbreak
signific
mortal
seen
previous
healthi
person
etiolog
agent
identifi
cov
term
sever
acut
respiratori
syndromeassoci
cov
sarscov
common
symptom
fever
myalgia
cough
follow
dyspnea
laboratori
marker
includ
lymphopenia
thrombocytopenia
elev
lactat
dehydrogenas
characterist
viral
pneumon
seen
chest
radiograph
sever
patient
given
intraven
oral
ribavirin
corticosteroid
often
advers
effect
hemolyt
anemia
hypocalcemia
liver
transplant
recipi
acquir
sar
follow
outpati
hospit
visit
fatal
outcom
infect
signific
number
health
care
worker
addit
tissu
level
sarscov
lung
transplant
recipi
sever
logfold
greater
immunocompet
patient
observ
transplant
recipi
led
term
supershedd
viru
although
spread
sarscov
eventu
control
effect
infect
control
measur
exercis
identif
manag
emerg
viru
provid
import
lesson
futur
transplant
patient
sentin
emerg
infect
immunosuppress
state
contact
health
care
system
addit
gener
higher
level
viru
secret
widespread
infect
commun
also
theoret
risk
transmiss
respiratori
viru
donor
recipi
especi
lung
transplant
also
theoret
organ
tissu
emerg
virus
also
import
hsct
sot
program
lead
complet
halt
transplant
activ
especi
resourc
need
divert
medic
manag
gener
popul
individu
program
must
review
strategi
care
transplant
patient
respiratori
viru
outbreak
adv
nonenvelop
dna
virus
least
known
serotyp
categor
serogroup
g
adv
capabl
caus
varieti
ill
respiratori
viru
transplant
immunocompet
immunocompromis
host
includ
urti
lrti
conjunct
keratoconjunct
pharyngoconjunctiv
fever
enter
hepat
enceph
dissemin
diseas
hsct
recipi
incid
report
sot
recipi
incid
note
variat
incid
depend
type
diagnost
techniqu
type
transplant
studi
age
incid
gener
higher
pediatr
popul
like
adv
popul
acquir
commun
possibl
donorderiv
infect
reactiv
diseas
diagnosi
made
indirect
method
serolog
method
directli
demonstr
presenc
viru
nat
cultur
dfa
sensit
test
adv
nat
situ
hybrid
immunohistochemistri
pcr
fix
tissu
also
identifi
adenoviru
monitor
adv
similar
cytomegaloviru
may
permit
earli
detect
certain
highrisk
set
monitor
adv
peripher
blood
seem
predict
diseas
cohort
allohsct
recipi
benefici
sot
recipi
surveil
studi
use
blood
pcr
adv
found
selflimit
adenoviremia
occur
sot
patient
asymptomat
although
adv
diseas
may
manifest
clinic
syndrom
transplant
patient
sever
case
advrel
hemorrhag
cystiti
also
describ
hsct
kidney
transplant
recipi
hofland
colleagu
review
case
adv
hemorrhag
cystiti
kidney
transplant
patient
case
occur
within
first
year
posttranspl
present
fever
dysuria
hematuria
graft
dysfunct
present
patient
viral
chang
acut
reject
may
seen
kidney
biopsi
adv
speci
b
predomin
serotyp
caus
diseas
specif
therapi
adv
acyclovir
ganciclovir
gener
activ
adv
encod
thymidin
kinas
vidarabin
vitro
activ
adv
also
use
treat
adv
hemorrhag
cystiti
howev
clinic
studi
focus
cidofovir
ribavirin
report
success
treatment
dissemin
diseas
cidofovir
intraven
immunoglobulin
ivig
also
use
conjunct
antivir
howev
ivig
may
contain
suffici
quantiti
antibodi
serotyp
adopt
transfer
cell
also
use
document
advspecif
tcell
respons
recipi
donor
lymphocyt
infus
also
attempt
overal
advrel
mortal
allogen
stem
cell
transplant
recipi
despit
antivir
especi
high
receiv
tcell
deplet
graft
mortal
rate
quit
high
adenovir
pneumonia
hepat
lower
although
signific
mortal
rate
hemorrhag
cystiti
coliti
also
seen
immun
reconstitut
play
import
role
clearanc
adv
decreas
dose
immunosuppress
medic
import
advanc
molecular
diagnost
techniqu
detect
broadrang
respiratori
virus
rhinoviru
like
frequent
detect
viru
rhinoviru
member
picornavirida
famili
well
accept
major
caus
urti
lrti
also
occur
especi
immunocompromis
host
one
review
patient
underli
hematolog
malign
rhinoviru
infect
lower
respiratori
tract
involv
present
case
onset
infect
progress
lrti
seen
fatal
case
hsct
patient
attribut
rhinoviru
also
describ
persist
chronic
infect
rhinoviru
also
describ
lung
transplant
recipi
may
lead
graft
dysfunct
lung
transplant
recipi
may
repeat
detect
rhinoviru
addit
likelihood
rhinovir
persist
increas
acquir
soon
transplant
detect
asymptomat
patient
howev
common
lowlevel
viral
load
rhinoviru
found
bronchoalveolar
lavag
specimen
mani
asymptomat
patient
pleconaril
specif
inhibitor
picornavirus
seem
effect
clinic
trial
immunocompet
person
rhinoviru
infect
longer
avail
specif
therapi
rhinoviru
manag
patient
rhinoviru
isol
unclear
intervent
like
necessari
asymptomat
patient
upper
respiratori
infect
present
mani
expert
suggest
decreas
exogen
immunosuppress
possibl
lower
tract
infect
immunosuppress
reduc
evid
adjunct
therapi
ivig
corticosteroid
therapi
antibacteri
prophylaxi
role
play
infect
parvoviru
singlestrand
dna
viru
genu
erythroviru
although
infect
nonspecif
flulik
ill
specif
clinic
syndrom
describ
children
parvoviru
caus
facial
rash
resembl
slap
cheek
adult
parvoviru
polyarthropathi
syndrom
viru
also
lead
transient
aplast
crisi
chronic
hemolyt
anemia
hydrop
fetali
lead
intrauterin
fetal
death
pregnant
women
onset
parvovirusassoci
syndrom
occur
time
posttranspl
describ
earli
week
acquisit
viru
like
caus
inhal
infect
aerosol
immunocompet
host
also
transmiss
donor
possibl
also
possibl
parvoviru
reactiv
although
littl
known
parvoviru
latenc
cellular
reservoir
parvoviru
isol
lower
respiratori
tract
lung
transplant
recipi
also
report
pneumon
transplant
recipi
infect
transplant
recipi
unlik
immunocompet
patient
viral
replic
persist
prolong
period
time
parvoviru
wellestablish
associ
hematolog
abnorm
includ
pure
red
cell
aplasia
acut
chronic
anemia
transplant
recipi
anemia
common
problem
transplant
recipi
import
search
parvoviru
case
unexplain
recalcitr
anemia
cell
lineag
may
also
affect
lead
leucopenia
thrombocytopenia
serolog
studi
limit
use
confound
transfus
immunoglobulin
therapi
addit
transplant
recipi
may
mount
antibodi
respons
instead
direct
detect
viru
qualit
quantit
dna
pcr
use
method
specif
antivir
therapi
parvoviru
infect
although
variou
manag
option
suggest
consist
decreas
immunosuppress
ivig
variou
dose
regimen
ivig
use
rang
gkg
day
human
bocaviru
recent
describ
member
parvovirida
famili
also
includ
parvoviru
parvoviru
first
descript
bocaviru
alland
colleagu
respiratori
secret
children
sinc
sever
studi
worldwid
seropreval
rang
viru
predominantli
found
children
mani
studi
show
associ
clinic
upper
lower
respiratori
tract
diseas
found
frequent
symptomat
rather
asymptomat
individu
also
found
copathogen
respiratori
virus
dissemin
diseas
bocaviru
report
child
pulmonari
infiltr
hsct
viru
detect
respiratori
blood
stool
specimen
whether
bocaviru
pathogen
adult
wellestablish
descript
adult
rare
miyaki
colleagu
find
bocaviru
bronchoalveolar
lavag
specimen
adult
lung
transplant
recipi
symptomat
nontranspl
control
detect
human
bocaviru
dna
primarili
base
pcr
methodolog
use
primer
specif
viral
gene
remain
research
tool
serolog
test
use
antibodi
specif
human
bocaviru
viral
capsid
protein
also
describ
readili
avail
test
bocaviru
clinic
set
although
could
potenti
ad
exist
multiplex
platform
futur
mani
respiratori
virus
specif
therapi
bocaviru
ki
wu
recent
describ
polyomavirus
also
associ
upper
lower
respiratori
tract
diseas
wu
first
describ
respiratori
specimen
australia
subsequ
respiratori
specimen
worldwid
patient
children
although
adult
also
among
cohort
associ
wu
ki
virus
diseas
debat
literatur
especi
given
coinfect
anoth
respiratori
viru
found
patient
limit
literatur
virus
transplant
set
studi
hospit
patient
respiratori
ill
ki
significantli
frequent
hsct
recipi
vs
p
anoth
studi
use
realtim
pcr
polyomaviru
detect
immunocompet
immunocompromis
patient
ki
viru
found
three
immunocompromis
patient
although
two
coinfect
make
difficult
interpret
extent
viru
pathogen
pcr
gener
exclus
method
detect
virus
studi
determin
signific
immunocompromis
host
communityacquir
rvi
occur
lung
transplant
associ
acut
reject
bo
sever
retrospect
prospect
studi
shown
associ
one
prospect
studi
follow
lung
transplant
recipi
rvi
compar
control
rvi
greater
incid
acut
reject
bo
death
risk
bo
rviposit
versu
rvineg
patient
studi
individu
viru
associ
progress
bo
howev
recent
studi
found
signific
percentag
lung
transplant
recipi
paramyxoviru
infect
progress
bo
rhinoviru
cov
addit
hmpv
compar
rsv
infect
lung
transplant
recipi
patient
respect
develop
graft
dysfunct
howev
progress
bo
seen
infect
rsv
virus
trigger
reject
progress
bo
unclear
mechan
like
cytokinemedi
inflammatori
cascad
recruit
cell
allograft
result
intralumin
prolifer
fibroblast
therapi
rvi
postlung
transplant
variabl
expert
agre
avail
specif
antivir
therapi
given
symptomat
infect
regardless
durat
symptom
circumst
decreas
immunosuppress
recommend
mani
posttranspl
viral
infect
includ
respiratori
virus
mani
expert
also
use
highdos
steroid
mgkgd
consecut
day
howev
presenc
absenc
specif
antivir
therapi
prevent
acut
reject
progress
bo
whether
specif
antivir
therapi
reduc
risk
progress
bosob
controversi
gener
infect
control
measur
respiratori
virus
includ
droplet
precaut
involv
place
patient
singl
room
person
enter
room
wear
gown
glove
mask
eye
protect
situat
surgic
mask
appropri
howev
contagi
virus
fittest
mask
requir
perform
procedur
face
shield
worn
neg
pressur
isol
also
suggest
virul
virus
outbreak
transplant
unit
follow
measur
may
reduc
transmiss
increas
patient
safeti
temporarili
discontinu
new
transplant
discharg
patient
admit
investig
elect
procedur
daili
screen
staff
symptom
respiratori
ill
send
ill
staff
home
promptli
minim
outpati
appoint
procedur
transplant
patient
outbreak
transplant
ward
inpati
offer
chemoprophylaxi
avail
exampl
influenza
outbreak
larg
hsct
center
oseltamivir
prophylaxi
mg
daili
shown
safe
welltoler
summari
rvi
continu
gain
import
transplant
oncolog
new
molecular
techniqu
allow
rapid
identif
identif
greater
number
virus
signific
newli
found
virus
immunosuppress
patient
continu
evolv
treatment
rvi
limit
infect
rsv
high
mortal
rate
despit
standard
antivir
therapi
prevent
infect
infect
control
measur
immun
pathogen
vaccin
avail
import
research
improv
diagnost
therapeut
option
popul
need
